Ignite Creation Date:
2024-05-06 @ 8:16 PM
Last Modification Date:
2024-10-26 @ 3:24 PM
Study NCT ID:
NCT06325748
Status:
RECRUITING
Last Update Posted:
2024-06-12
First Post:
2024-03-13
Brief Title:
SENTI-202 Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 andor FLT3 Blood Cancers Including AMLMDS
Sponsor:
Senti Biosciences
Organization:
Senti Biosciences
Conditions & Keywords Data
Conditions:
| Name |
|---|
| AMLMDS |
| CD33 Expressing Hematological Malignancies |
| FLT3 Expressing Hematological Malignancies |
Keywords:
| Name | View |
|---|---|
| endomucin | View |
| SENTI-202 | View |
| CAR NK | View |
| natural killer cell | View |
| CD33 | View |
| FLT3 | View |
| allogeneic | View |
| logic gate | View |
| relapsedrefractory AML | View |
| relapsedrefractory MDS | View |
| inhibitory CAR | View |
| activating CAR | View |
| NOT logic gate | View |
| IL15 | View |
| interleukin 15 | View |
| cell therapy | View |
| off-the-shelf | View |
| leukemic stem cells | View |
| blastic plasmacytoid dendritic cell neoplasm BPDCN | View |
| multiple myeloma MM | View |
| mixed phenotype acute leukemia MPAL | View |